STAT November 20, 2023
Richard Burr

Cell and gene therapies are the next frontier in medicine and promise long-sought hope for people living with incurable and fatal conditions. As their promise increasingly becomes reality, the FDA’s gatekeeping role is important.

To truly serve the people who need these medications, the FDA must be a good-faith partner and deploy the tools my fellow congressional lawmakers and I helped secure.

We are finally beginning to realize the results of decades of cell and gene therapy investments, fostered by repeated bipartisan legislation to help advance the scientific technology capable of addressing diseases at the DNA level. Despite signs of progress and a strong commitment from FDA leadership to improve its readiness for these cutting-edge therapies, the agency remains far...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article